- Clinical trials for NG101 show smooth progress from low-dose to medium-dose (Cohort 2) 44-week results to be unveiled - Selected to present in the gene therapy session alongside Eli Lilly, validating technological excellence - Reyon Pharmaceutical to exclusively handle global production and supply of NG101 via its Chungju GMP facility Elisigen, a gene therapy research and development company and a partner of REYON PHARM, announced that it will present the 44-week interim results of its Phase ...

- Leading Japanese gene therapy companies are scheduled to visit the Chungju Smart Plant. - Possibility of collaboration on AAV and pDNA manufacturing ahead of global clinical trials and commercialization. - Visits from European multinationals and large domestic pharmaceutical companies continue, drawing increased industry attention. Major gene therapy development companies from Japan are reported to make a series of visits to Reyon Pharmaceuticals Chungju Smart Plant this coming July. The indu...

Reyon Pharmaceutical is adding a new cash cow, capturing opportunities arising from structural shifts in the domestic hemostatic agent market. The companys efforts to expand its business for thrombin, a core ingredient in hemostats, are projected to yield tangible results starting in the second half of this year. Reyon Pharmaceutical announced on the 9th that it is focusing on strengthening its competitiveness in the thrombin market by expanding development collaborations with a multiple number...

Reyon Pharmaceutical is strengthening the competitiveness of NG101, a gene therapy for wet age-related macular degeneration (wet AMD) co-developed with Elysigen (formerly Neuracle Genetics). The company plans to reaffirm its unrivaled efficacy by disclosing additional data from the Phase 1/2a clinical trial in the second half of this year. Furthermore, it is pursuing indication expansion into dry AMD, which represents a significantly larger market size. Consequently, the Chungju Smart Plant is ...